April 15, 2021
Clinical diagnostic company Renalytix AI has expanded its partnership with the Joslin Diabetes Center to integrate new biomarkers for kidney disease discovered by the center's researchers into the company’s KidneyIntelX platform.
KidneyIntelX is an in vitro diagnostic platform that assesses the risk of adverse kidney outcomes in patients with Type 2 diabetes and early-stage kidney disease. By...
January 6, 2017
While digital health doesn't have as big of a presence at the Consumer Electronics Show in Las Vegas as other industries, there were a fair number of wearables, apps and sensor-enabled tools showcased. There were also several partnerships announced, which you can read about here. Some have already been covered in MobiHealthNews yet didn't make their official debuts til this week, but most were...
October 18, 2016
Common Sensing, a Cambridge-based company developing a smart connected insulin pen cap, announced that it will test its device in a clinical trial in collaboration with Joslin Diabetes Center, Sanofi, and Dexcom.
The study of 125 subjects will be conducted by Joslin and funded by Sanofi. Patients will be given a Gocap from Common Sensing, a cap that fits on to a disposable insulin pen and can...
September 23, 2015
Glooko and Joslin's HypoMap
Joslin Diabetes Center is running a small trial to pilot test a mobile health app and an online nutrition education platform for people with Type 1 diabetes, according to a ClinicalTrials.gov posting.
The web platform will help educate patients about how to optimize their glucose and analyze their after-meal behavior. The app will facilitate data logging to help...
August 31, 2015
Sanofi's IBG Star connected glucometer.
Google Life Science's recently-announced partnership with Dexcom (not to mention its contact lens project with Novartis) have already made it clear that diabetes is a focus for the company. Now the company is making that focus official in a new partnership with Sanofi and the Joslin Diabetes Center.
"Today, we’re announcing a new partnership with Sanofi...
June 17, 2015
Pfizer Head of Clinical Innovation Craig Lipset
In 2011, Pfizer announced a novel clinical trial that would be fully remote, with every aspect of the trial being handled either online, over the phone, or by mail. But that trial was cancelled due to a failure to recruit enough participants, and a promised mulligan never emerged.
Craig Lipset, Pfizer's Head of Clinical Innovation, said at the...
March 18, 2015
San Francisco-based Conversa Health, which makes a digital patient engagement platform, has raised $2.5 million from undisclosed healthcare-focused angel investors. The company also announced the appointment of a new chief technology officer and the formation of its medical advisory board. This is the first funding announcement from the StartUp Health member.
The round will bolster Conversa's...
March 2, 2015
Going "beyond the pill" doesn't just mean devising new digital technologies to market a drug or promote medication adherence with software tools. Sometimes it means engaging patients in their patient journey long before a drug enters into the equation -- and hoping it pays dividends later on.
Jeremy Shepler, senior director of diabetes marketing at Novo Nordisk, spoke at the ePharma Summit last...
August 7, 2014
Dexcom Guide, the company's current education-only app
Continuous glucose monitor maker Dexcom announced that it will partner with insulin pump maker Silicon Valley-based Asante Solutions so that users of Asante devices will be able to access that data from Dexcom's not-yet launched smartphone app.
Dexcom already offers one app that helps people with diabetes watch training videos, read...
June 11, 2014
HypoMap, a tool created by Glooko in partnership with Joslin
Boston-based Joslin Diabetes Center has created a new non-profit division, called Joslin Institute for Technology Translation (JITT), so that the healthcare organization can collaborate with companies currently developing tools for people with diabetes, according to a press release.
"Working with our CEO John Brooks, we thought that...